<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01854827</url>
  </required_header>
  <id_info>
    <org_study_id>P007 PRIME</org_study_id>
    <secondary_id>U01DK062456</secondary_id>
    <nct_id>NCT01854827</nct_id>
  </id_info>
  <brief_title>Safety Study of Intravenous Immunoglobulin (IVIG) Post-Portoenterostomy in Infants With Biliary Atresia</brief_title>
  <acronym>PRIME</acronym>
  <official_title>A Phase 1/2A Trial of Intravenous Immunoglobulin (IVIG) Therapy Following Portoenterostomy in Infants With Biliary Atresia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Children Liver Disease Research and Education Network (ChiLDREN) is conducting a clinical
      trial to determine the feasibility, acceptability, tolerability and safety profile of IVIG
      treatment administered to infants after hepatic portoenterostomy (HPE) for biliary atresia,
      as well as investigate preliminary evidence of activity and explore mechanisms of action.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this multicenter prospective phase 1/2A open label trial, the feasibility, tolerability
      and safety of intravenous immunoglobulin (IVIG) therapy following hepatic portoenterostomy
      (HPE) will be assessed in 29 infants with biliary atresia (BA), efficacy will be estimated
      and exploratory mechanistic research studies will be performed. After written consent is
      obtained from the parent or guardian, the subject will be enrolled and will receive three
      intravenous doses of IVIG at designated intervals over the first 60 days following HPE and
      will be followed for 360 days after enrollment. Blood will also be obtained during this study
      to assess potential mechanisms by which the IVIG may alter or reduce bile duct inflammation
      and injury and improve bile flow. All infants in this trial will also be treated with
      standardized doses of other routine standard-of-care treatments for BA during this trial
      (ursodeoxycholic acid, trimethoprim-sulfamethoxasole, and fat-soluble vitamin supplements).
      This routine clinical care will not be modified by participation in this study. Subjects in
      this study will not receive corticosteroid therapy for treatment of biliary atresia, as this
      is of unproven benefit at the present time.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility of IVIG Treatment</measure>
    <time_frame>60 days post-HPE</time_frame>
    <description>Percentage of subjects for whom administration of IVIG is feasible, defined as the successful administration (at least 80% of each dose) of all 3 doses of IVIG</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Acceptability of IVIG</measure>
    <time_frame>60 days post-HPE</time_frame>
    <description>Percentage of subjects for whom the study is acceptable, defined as the ability of the subject's family or guardian to allow intravenous line placements, blood draws, and other study procedures for the study subjects.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serious Adverse Events</measure>
    <time_frame>360 days post-HPE</time_frame>
    <description>Percentage of subjects with any serious adverse events (SAEs) prior to liver transplant</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Level 3-5 Toxicity</measure>
    <time_frame>360 days post-HPE</time_frame>
    <description>Percentage of subjects with any level 3, 4, or 5 toxicity (per NCI CTEP grading system)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>360 days post-HPE</time_frame>
    <description>Percentage of subjects with other expected adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Good Bile Drainage at 90 Days Post-HPE</measure>
    <time_frame>90 days post-HPE</time_frame>
    <description>Percentage of subjects who survive 90 days after HPE with both their native liver and serum total bilirubin &lt;1.5 mg/dL at 90 days after HPE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Good Bile Drainage at 180 Days Post-HPE</measure>
    <time_frame>180 days post-HPE</time_frame>
    <description>Percentage of subjects who survive 180 days after HPE with both their native liver and serum total bilirubin &lt;1.5 mg/dL at 180 days after HPE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Good Bile Drainage at 360 Days Post-HPE</measure>
    <time_frame>360 days post-HPE</time_frame>
    <description>Percentage of subjects who survive 360 days after HPE with both their native liver and serum total bilirubin &lt;1.5 mg/dL at 360 days after HPE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transplant-free Survival</measure>
    <time_frame>360 days post-HPE</time_frame>
    <description>Percentage of subjects who survive with their native liver at 360 days after HPE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating Regulatory T-Cells, Inflammatory Cytokines, and Specific Autoantibodies.</measure>
    <time_frame>Over 360 days after HPE</time_frame>
    <description>Percentage and absolute number of Tregs (CD4+CD25+FoxP3+), CD3/4 T cells, CD3/8 T cells, NK cells (CD56), NK T cells (CD3/56), CD19/20 B cells, macrophages (CD14/11b), and neutrophils; plasma levels of anti-enolase antibody; and plasma cytokine levels (Th1/Th2 multiplex and IL17)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Biliary Atresia</condition>
  <arm_group>
    <arm_group_label>IVIG active treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous immunoglobulin (IVIG) 10% 1 gm/kg body weight/dose Day 3-5,30, 60 post HPE</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous immunoglobulin (IVIG)</intervention_name>
    <description>All participants will receive the same dose of IVIG at the same intervals in an open-label fashion as long as the subject does not have any increased risk for toxicity for any IVIG infusion. IVIG will be initiated on day 3 (up to day 5) after HPE surgery (HPE is day 0) at a dose of 1 gm/kg body weight by slow intravenous infusion over at least 4 hours. The same dose (1 gm/kg) and duration of infusion will be repeated on day 30 and day 60 after HPE.</description>
    <arm_group_label>IVIG active treatment</arm_group_label>
    <other_name>Gamunex-C®</other_name>
    <other_name>Gamunex®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Infant under 120 days old with established diagnosis of BA. Subjects in this trial
             must start treatment within 3-5 days of the Kasai procedure and be part of a
             prospective study of the natural history of biliary atresia also being conducted by
             ChiLDREN (http://www.clinicaltrials.gov/ct/show/NCT00061828?order=3).

          -  Standard HPE operation has been performed for BA within the previous 3 days

          -  Post-conception age ≥ 36 weeks at time of enrollment

          -  Weight at enrolment ≥ 2000 gm

          -  Written informed consent to participate in the study obtained within 3 days of
             completion of HPE.

        Exclusion Criteria:

          -  Laparoscopic HPE or &quot;gall bladder Kasai&quot; (cholecysto-portostomy) surgery was performed

          -  Biliary atresia splenic malformation syndrome (presence of asplenia, polysplenia or
             double spleen)

          -  History of a hypercoagulable disorder

          -  Renal Disease defined as serum creatinine &gt; 1.0 mg/dl prior to enrollment or presence
             of complex renal anomalies found on imaging

          -  Evidence of congestive heart failure or fluid overload

          -  Presence of significant systemic hypertension for age (defined as persistent systolic
             blood pressure ≥112 mmHg measured on at least 3 occasions following HPE)

          -  Infants whose mother is known to have human immunodeficiency virus infection

          -  Infants whose mother is known to be serum HBsAg or hepatitis C virus antibody positive

          -  Previous treatment with intravenous immunoglobulin therapy or corticosteroid therapy

          -  Previous treatment with any other investigational agent

          -  History of allergic reaction to any human blood product infusion

          -  Infants with other severe concurrent illnesses, such as neurological, cardiovascular,
             pulmonary, metabolic, endocrine, and renal disorders, that would interfere with the
             conduct and results of the study

          -  Any other clinical condition that is a contraindication to the use of IVIG
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>120 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald Sokol, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Children's Hospital Colorado</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ed Doo, MD</last_name>
    <role>Study Director</role>
    <affiliation>National Institute of Diabetes and Digestive and Kidney Disease (NIDDK)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Averell Sherker, MD</last_name>
    <role>Study Director</role>
    <affiliation>National Institute of Diabetes and Digestive and Kidney Disease (NIDDK)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital at Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://childrennetwork.org/</url>
    <description>Click here for more information about the Children Liver Disease Research and Education Network (ChiLDREN)</description>
  </link>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 27, 2012</study_first_submitted>
  <study_first_submitted_qc>May 13, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 16, 2013</study_first_posted>
  <results_first_submitted>April 6, 2018</results_first_submitted>
  <results_first_submitted_qc>April 6, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">May 11, 2018</results_first_posted>
  <last_update_submitted>April 6, 2018</last_update_submitted>
  <last_update_submitted_qc>April 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Biliary atresia</keyword>
  <keyword>Hepatic portoenterostomy</keyword>
  <keyword>Intravenous immunoglobulin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Biliary Atresia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>IVIG Active Treatment</title>
          <description>Intravenous immunoglobulin (IVIG) 10% 1 gm/kg body weight/dose Day 3-5,30, 60 post HPE
Intravenous immunoglobulin (IVIG): All participants will receive the same dose of IVIG at the same intervals in an open-label fashion as long as the subject does not have any increased risk for toxicity for any IVIG infusion. IVIG will be initiated on day 3 (up to day 5) after HPE surgery (HPE is day 0) at a dose of 1 gm/kg body weight by slow intravenous infusion over at least 4 hours. The same dose (1 gm/kg) and duration of infusion will be repeated on day 30 and day 60 after HPE.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>MITT (Modified Intent-to-Treat) defined as all patients receiving at least one does of IVIG and maintaining eligibility throughout the trial.</population>
      <group_list>
        <group group_id="B1">
          <title>IVIG Active Treatment</title>
          <description>Intravenous Immunoglobulin (IVIG) active treatment for infants with biliary atresia</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="29"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.0" spread="18.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Ethnicity</title>
              <category_list>
                <category>
                  <title>Hispanic</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non-Hispanic</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Feasibility of IVIG Treatment</title>
        <description>Percentage of subjects for whom administration of IVIG is feasible, defined as the successful administration (at least 80% of each dose) of all 3 doses of IVIG</description>
        <time_frame>60 days post-HPE</time_frame>
        <population>MITT</population>
        <group_list>
          <group group_id="O1">
            <title>IVIG Active Treatment</title>
            <description>Intravenous Immunoglobulin (IVIG) active treatment for infants with biliary atresia</description>
          </group>
        </group_list>
        <measure>
          <title>Feasibility of IVIG Treatment</title>
          <description>Percentage of subjects for whom administration of IVIG is feasible, defined as the successful administration (at least 80% of each dose) of all 3 doses of IVIG</description>
          <population>MITT</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Proportion was evaluated relative to 80% where statistical superiority was demonstrated if the one-sided, 90% Clopper-Pearson lower confidence bound was &gt; 80%.</non_inferiority_desc>
            <param_type>proportion of patients</param_type>
            <param_value>79.3</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>63.2</ci_lower_limit>
            <other_analysis_desc>The lower bound of the 90% Clopper-Pearson confidence interval was &lt; 80%, therefore the study failed to achieve the feasibility definition stated in the protocol.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Acceptability of IVIG</title>
        <description>Percentage of subjects for whom the study is acceptable, defined as the ability of the subject's family or guardian to allow intravenous line placements, blood draws, and other study procedures for the study subjects.</description>
        <time_frame>60 days post-HPE</time_frame>
        <population>MITT</population>
        <group_list>
          <group group_id="O1">
            <title>IVIG Active Treatment</title>
            <description>Intravenous Immunoglobulin (IVIG) active treatment for infants with biliary atresia</description>
          </group>
        </group_list>
        <measure>
          <title>Acceptability of IVIG</title>
          <description>Percentage of subjects for whom the study is acceptable, defined as the ability of the subject's family or guardian to allow intravenous line placements, blood draws, and other study procedures for the study subjects.</description>
          <population>MITT</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Proportion was evaluated relative to 80% where statistical superiority was demonstrated if the one-sided, 90% Clopper-Pearson lower confidence bound was &gt; 80%.</non_inferiority_desc>
            <param_type>proportion of patients</param_type>
            <param_value>79.3</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>63.2</ci_lower_limit>
            <other_analysis_desc>The lower bound of the 90% Clopper-Pearson confidence interval was &lt; 80%, therefore the study failed to achieve the feasibility definition stated in the protocol.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Serious Adverse Events</title>
        <description>Percentage of subjects with any serious adverse events (SAEs) prior to liver transplant</description>
        <time_frame>360 days post-HPE</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>IVIG Active Treatment</title>
            <description>Intravenous Immunoglobulin (IVIG) active treatment for infants with biliary atresia</description>
          </group>
        </group_list>
        <measure>
          <title>Serious Adverse Events</title>
          <description>Percentage of subjects with any serious adverse events (SAEs) prior to liver transplant</description>
          <population>mITT</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Proportions with serious AEs prior to liver transplant were calculated, along with one-sided 90% Clopper-Pearson confidence interval lower bounds.</non_inferiority_desc>
            <param_type>proportion of patients</param_type>
            <param_value>89.7</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>75.4</ci_lower_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Level 3-5 Toxicity</title>
        <description>Percentage of subjects with any level 3, 4, or 5 toxicity (per NCI CTEP grading system)</description>
        <time_frame>360 days post-HPE</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>IVIG Active Treatment</title>
            <description>Intravenous Immunoglobulin (IVIG) active treatment for infants with biliary atresia</description>
          </group>
        </group_list>
        <measure>
          <title>Level 3-5 Toxicity</title>
          <description>Percentage of subjects with any level 3, 4, or 5 toxicity (per NCI CTEP grading system)</description>
          <population>mITT</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Proportion of patients with level 3-5 toxicity are presented along with one-sided 90% Clopper-Pearson confidence interval lower bound.</non_inferiority_desc>
            <param_type>proportion of patients</param_type>
            <param_value>89.7</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>75.4</ci_lower_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Adverse Events</title>
        <description>Percentage of subjects with other expected adverse events</description>
        <time_frame>360 days post-HPE</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>IVIG Active Treatment</title>
            <description>Intravenous Immunoglobulin (IVIG) active treatment for infants with biliary atresia</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events</title>
          <description>Percentage of subjects with other expected adverse events</description>
          <population>mITT</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Proportion of patients with other expected AEs are presented along with one-sided 90% Clopper-Pearson confidence limit lower bound.</non_inferiority_desc>
            <param_type>proportion of patients</param_type>
            <param_value>27.6</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>14.5</ci_lower_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Good Bile Drainage at 90 Days Post-HPE</title>
        <description>Percentage of subjects who survive 90 days after HPE with both their native liver and serum total bilirubin &lt;1.5 mg/dL at 90 days after HPE</description>
        <time_frame>90 days post-HPE</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>IVIG Active Treatment</title>
            <description>Intravenous Immunoglobulin (IVIG) active treatment for infants with biliary atresia</description>
          </group>
        </group_list>
        <measure>
          <title>Good Bile Drainage at 90 Days Post-HPE</title>
          <description>Percentage of subjects who survive 90 days after HPE with both their native liver and serum total bilirubin &lt;1.5 mg/dL at 90 days after HPE</description>
          <population>mITT</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>IVIG was compared to the historical placebo control from the START study (n=64).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>One-sided testing for superiority of IVIG to historical control.</non_inferiority_desc>
            <p_value>0.5486</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.67</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_upper_limit>2.38</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Good Bile Drainage at 180 Days Post-HPE</title>
        <description>Percentage of subjects who survive 180 days after HPE with both their native liver and serum total bilirubin &lt;1.5 mg/dL at 180 days after HPE</description>
        <time_frame>180 days post-HPE</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>IVIG Active Treatment</title>
            <description>Intravenous Immunoglobulin (IVIG) active treatment for infants with biliary atresia</description>
          </group>
        </group_list>
        <measure>
          <title>Good Bile Drainage at 180 Days Post-HPE</title>
          <description>Percentage of subjects who survive 180 days after HPE with both their native liver and serum total bilirubin &lt;1.5 mg/dL at 180 days after HPE</description>
          <population>mITT</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>IVIG was compared for superiority to the historical control of START study placebo (N=64).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>One-sided testing for superiority of IVIG relative to historical control.</non_inferiority_desc>
            <p_value>0.8455</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.33</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_upper_limit>1.22</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Good Bile Drainage at 360 Days Post-HPE</title>
        <description>Percentage of subjects who survive 360 days after HPE with both their native liver and serum total bilirubin &lt;1.5 mg/dL at 360 days after HPE</description>
        <time_frame>360 days post-HPE</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>IVIG Active Treatment</title>
            <description>Intravenous Immunoglobulin (IVIG) active treatment for infants with biliary atresia</description>
          </group>
        </group_list>
        <measure>
          <title>Good Bile Drainage at 360 Days Post-HPE</title>
          <description>Percentage of subjects who survive 360 days after HPE with both their native liver and serum total bilirubin &lt;1.5 mg/dL at 360 days after HPE</description>
          <population>mITT</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>IVIG was compared for superiority to the historical START placebo control (N=64).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>One-sided.</non_inferiority_desc>
            <p_value>0.8431</p_value>
            <p_value_desc>One-sided</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.29</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_upper_limit>1.24</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Transplant-free Survival</title>
        <description>Percentage of subjects who survive with their native liver at 360 days after HPE.</description>
        <time_frame>360 days post-HPE</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>IVIG Active Treatment</title>
            <description>Intravenous Immunoglobulin (IVIG) active treatment for infants with biliary atresia</description>
          </group>
        </group_list>
        <measure>
          <title>Transplant-free Survival</title>
          <description>Percentage of subjects who survive with their native liver at 360 days after HPE.</description>
          <population>mITT</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>K-M estimates for survival for IVIG vs the historical START placebo control are provided, along with one-sided 90% upper bounds of the confidence intervals.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>One-sided for IVIG superior to historical START placebo control.</non_inferiority_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-11.9</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_upper_limit>2.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Circulating Regulatory T-Cells, Inflammatory Cytokines, and Specific Autoantibodies.</title>
        <description>Percentage and absolute number of Tregs (CD4+CD25+FoxP3+), CD3/4 T cells, CD3/8 T cells, NK cells (CD56), NK T cells (CD3/56), CD19/20 B cells, macrophages (CD14/11b), and neutrophils; plasma levels of anti-enolase antibody; and plasma cytokine levels (Th1/Th2 multiplex and IL17)</description>
        <time_frame>Over 360 days after HPE</time_frame>
        <posting_date>05/2018</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was collected from enrollment into the study until the earlier of the Day 365 visit or withdrawal from the study.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>IVIG Active Treatment</title>
          <description>Intravenous Immunoglobulin (IVIG) active treatment for infants with biliary atresia</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic</sub_title>
                <counts group_id="E1" events="20" subjects_affected="12" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Immunological</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infectious</sub_title>
                <counts group_id="E1" events="63" subjects_affected="21" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Nutritional</sub_title>
                <counts group_id="E1" events="13" subjects_affected="10" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplastic</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Surgical</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Post Operative Liver Transplant</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Elevation in Systolic BP &gt; 112</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Emesis</sub_title>
                <counts group_id="E1" events="21" subjects_affected="11" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Reflux</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Vomitting</sub_title>
                <counts group_id="E1" events="20" subjects_affected="14" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="168" subjects_affected="28" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Increased Sleepiness</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Oral Thrush</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="21" subjects_affected="16" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Elevated Bilirubin</sub_title>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Elevated INR</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Elevation in AST and/or ALT</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Hepatic</sub_title>
                <counts group_id="E1" events="24" subjects_affected="13" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Increased PT/INR</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Immunological</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="51" subjects_affected="18" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Infectious</sub_title>
                <counts group_id="E1" events="63" subjects_affected="21" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Otitis Media</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased Feeding</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Feeding Intolerance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Inadequate wait gain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Metabolic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Nutritional</sub_title>
                <counts group_id="E1" events="13" subjects_affected="10" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Poor Weight Gain</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplastic</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Fussiness</sub_title>
                <counts group_id="E1" events="7" subjects_affected="3" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="19" subjects_affected="10" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Acholic Stools</sub_title>
                <counts group_id="E1" events="22" subjects_affected="14" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="17" subjects_affected="12" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" events="15" subjects_affected="9" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic Reaction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Allergic Rhinitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Cold Systems</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Congestion</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Difficulty Breathing</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Nasal Congestion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>RSV</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Infection</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Diaper Rash</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Pruitis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Post Operative Liver Transplant</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Surgical</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>DCC PI</name_or_title>
      <organization>University of Michigan</organization>
      <phone>734-936-3585</phone>
      <email>mageej@med.umich.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

